Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Authors:
- Solange PetersSPSolange Peters
- Luis G. Paz-AresLPLuis G. Paz-Ares
- Martin ReckMRMartin Reck
- David P. CarboneDCDavid P. Carbone
- Julie R. BrahmerJBJulie R. Brahmer
- Hossein BorghaeiHBHossein Borghaei
- Kenneth J. O’byrneKenneth J. O’byrne
- Thomas JohnTJThomas John
- Tudor-Eliade CiuleanuTCTudor-Eliade Ciuleanu
- Michael SchenkerMSMichael Schenker
- Reyes Bernabe CaroRCReyes Bernabe Caro
Open Access
- 4 October 2024
- journal article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 20 (1) , 94-108
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb Co
This publication has 24 references indexed in Scilit:
- Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialEuropean Journal of Cancer, 2024
- A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON StudyClinical Lung Cancer, 2024
- Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1Journal of Thoracic Oncology, 2023
- Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 TrialJournal of Thoracic Oncology, 2023
- Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysisAnnals of Oncology, 2022
- First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic MutationsJournal of Thoracic Oncology, 2022
- Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817Journal of Thoracic Oncology, 2022
- Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the LungClinical Lung Cancer, 2022
- Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III TrialJournal of Thoracic Oncology, 2020